Jefferies Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jefferies Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,000	Closed	-$391K	–	1510
2020 Q2	$391K	Buy	+5,000	New	+$331K	﹤0.01%	959
2016 Q4	–	Sell	-17,600	Closed	-$1.25M	–	2424
2016 Q3	$1.25M	Sell	17,600 -9,200	-34%	-$587K	0.01%	1175
2016 Q2	$1.31M	Hold	26,800	–	–	0.01%	1052
2016 Q1	$1.7M	Buy	+26,800	New	+$1.75M	0.01%	925
2015 Q4	–	Sell	-39,700	Closed	-$3.82M	–	2509
2015 Q3	$3.82M	Buy	+39,700	New	+$4.55M	0.02%	606

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jefferies Group's RARE Position: Q2 2021 in Review

Jefferies Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 12,133 shares — an estimated $1.38M sold.

Jefferies Group first reported a position in RARE in Q3 2015 and held it in 5 quarters. The position peaked at $2.42M in Q2 2020. 242 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Jefferies Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 12,133 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $1.38M.
Jefferies Group first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 5 quarters.
Jefferies Group's Ultragenyx Pharmaceutical position peaked at $2.42M in Q2 2020.
242 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.